What is Kisspeptin?

Kisspeptin is a KISS1-derived neuropeptide family that activates the KISS1 receptor and sits upstream of GnRH in reproductive hormone control. [1][2][3]

Human research has tested kisspeptin as a way to stimulate LH, FSH, ovulation, and reproductive-axis signaling in fertility and hypothalamic-amenorrhea contexts. [1][2][3]

Kisspeptin is not the same as gonadorelin or hCG. It stimulates the reproductive axis upstream, while gonadorelin is GnRH and hCG acts downstream at the LH receptor. [1][2][3]

What Kisspeptin is investigated for

Kisspeptin evidence is grouped by practical use case and injectable and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

IVF oocyte maturation trigger

Injectable

65% Moderate

IVF triggering has the most concrete kisspeptin reproductive evidence, though not as a routine consumer protocol. [2][13][3]

Human evidence

Human IVF studies evaluated kisspeptin-54 to trigger oocyte maturation, including women at high risk of ovarian hyperstimulation syndrome. [2][13][3]

Animal / mechanistic evidence

The IVF trigger rationale follows kisspeptin activation of the GnRH-gonadotropin axis. [2][13][3]

Reproductive hormone regulation

Injectable, Intranasal

60% Emerging

Hormone-axis regulation is human-studied but broader than IVF triggering and should be graded separately. [4][1][6]

Human evidence

Intranasal kisspeptin rapidly stimulated gonadotropin release in humans, and reviews support its role in reproductive health and disease. [4][1][6]

Animal / mechanistic evidence

Kisspeptin-GnRH pathway biology explains acute LH/FSH responses and reproductive-axis interest. [4][1][6]

Sexual desire and arousal

Injectable

58% Emerging

Sexual desire and arousal have distinct human-study support beyond reproductive-hormone physiology. [26][27][1]

Human evidence

Randomized clinical trials evaluated kisspeptin effects on sexual brain processing and arousal-related measures in men and women with HSDD. [26][27][1]

Animal / mechanistic evidence

The rationale is central reproductive and limbic pathway signaling rather than peripheral erectile pharmacology. [26][27][1]

Puberty diagnostics and intervention

Injectable, Intranasal

52% Emerging

Puberty-related evidence remains pathway-based and lower confidence than IVF or acute hormone-response studies. [1][5]

Human evidence

Human reproductive-axis reviews discuss kisspeptin signaling in pubertal development and reproductive disease, but routine diagnostic or intervention use is not established. [1][5]

Animal / mechanistic evidence

The puberty rationale follows kisspeptin-GnRH pathway control of gonadotropin release. [1][5]

Evidence snapshot

Overall confidence

Moderate

65%

Kisspeptin has moderate support for supervised reproductive-endocrine stimulation in fertility research. General libido or hormone-boosting uses are weaker. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

65%

Human evidence

Moderate

Human fertility studies show reproductive-axis activity, including oocyte maturation and hormone-response settings. [1][2][3][4]

34%

Animal / preclinical

Limited

KISS1 receptor biology directly supports GnRH and gonadotropin signaling. [1][2][3][4]

65%

Mechanism support

Moderate

Kisspeptin activates KISS1 receptors on or near GnRH neurons, increasing GnRH pulse signaling and downstream LH and FSH release. The mechanism turns on the reproductive hormone cascade. [1][2][3][4]

Forms & administration

Kisspeptin is tracked as an injectable reproductive-hormone signaling peptide. Common protocol discussions are separate from supervised fertility or endocrine-testing designs. [10][1][2]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols usually use 100-300 mcg per dose. [10][1][2]

Frequency

Common injectable schedules use 2-3 doses weekly, while clinic protocols may be cycle- or lab-timed. [10][1][2]

Timing Considerations

Evening or pre-event timing is the common anchor; fertility-study timing depends on cycle phase and hormone testing. [10][1][2]

Cycle Length

Common injectable blocks run 4-8 weeks before comparing libido, hormone labs, cycle context, and adverse-effect notes. [10][1][2]

What to expect

Same day

Injectable kisspeptin can produce acute reproductive-hormone movement in supervised study settings, while felt libido effects are usually more subtle. [1][2][3][4][10]

Weeks 4-8

Injectable reproductive-axis blocks may show changes in libido, cycle context, hormone labs, and fertility-treatment response. [1][2][3][4][10]

After stopping

Reproductive-axis stimulation returns toward the underlying baseline after injectable kisspeptin exposure ends. [1][2][3][4][10]

Safety profile

Kisspeptin safety is reproductive-axis focused: hormone response, fertility-cycle context, sex-steroid-sensitive conditions, and injectable product quality matter. [1][2][3][4]

Cautions

Fertility-cycle response [1][2][3][4]
Hormone-sensitive conditions [1][2][3][4]
Pregnancy context [1][2][3][4]
Product quality [1][2][3][4]

What we don't know

Repeated non-clinic use, long-term reproductive-axis effects, sex-specific dosing, and interaction data remain limited. [1][2][3][4]

Who Kisspeptin is not for

Route-specific avoid and medical-review notes:

Pregnancy unless specifically supervised
Pregnancy unless specifically supervised warrants medical review or avoidance for Kisspeptin. [1][2][3][4]
Hormone-sensitive cancer without specialist review
Hormone-sensitive cancer without specialist review warrants medical review or avoidance for Kisspeptin. [1][2][3][4]
Ovarian hyperstimulation risk without clinic oversight
Ovarian hyperstimulation risk without clinic oversight warrants medical review or avoidance for Kisspeptin. [1][2][3][4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Fertility hormones
Gonadotropins, GnRH drugs, clomiphene, or letrozole can compound reproductive-axis response and ovarian-stimulation risk; this is a theoretical pathway caution. [1][2][3][4]
Sex-steroid therapy
Testosterone, estrogen, progestins, or antiandrogens can mask or amplify downstream hormone-response signals; this is a theoretical pathway caution. [1][2][3][4]
Dopamine / prolactin drugs
Dopamine agonists, dopamine antagonists, or prolactin-active drugs can make reproductive-axis symptoms harder to interpret; this is a theoretical pathway caution. [1][2][3][4]

Regulatory status

United States

In the U.S. as of 2026-06-21, Kisspeptin is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [17][10][11][15][16]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Kisspeptin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [10][11][15][16]	Flagged FDA safety-risk materials flag Kisspeptin-10 for immunogenicity, peptide-impurity, API-characterization, and limited proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [17][10][11][15][16]

Injectable

FDA drug approval

Not Approved

Kisspeptin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [10][11][15][16]

503A compounding

Flagged

FDA safety-risk materials flag Kisspeptin-10 for immunogenicity, peptide-impurity, API-characterization, and limited proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [17][10][11][15][16]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [18][19][20][21]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Kisspeptin injectable route as athlete-cleared without sport-specific review. [12][10][11][15][16]

How it works

Kisspeptin activates KISS1 receptors on or near GnRH neurons, increasing GnRH pulse signaling and downstream LH and FSH release. In plain terms, it can turn on the upstream reproductive hormone cascade when the axis can respond. [1][2][3][4]

For injectable use, timing and baseline endocrine state are part of the mechanism. Sex, cycle phase, ovarian reserve, fertility-treatment setting, and pituitary-gonadal responsiveness change the LH and FSH response, so it is not a generic libido or testosterone booster. Route-matched monitoring matters because overstimulation can change ovarian-risk interpretation. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about Kisspeptin:

A key evidence gap is dose-response by sex and cycle phase. [1][2][3][4]

A key evidence gap is long-term repeated use outside fertility care. [1][2][3][4]

A key evidence gap is clear comparisons with GnRH and hCG protocols. [1][2][3][4]

Common questions

Is kisspeptin FDA-approved?

No. Kisspeptin is not FDA-approved in the U.S. for injectable drug use, and FDA lists Kisspeptin-10 with compounding safety concerns. [10][11][1][2][17][15]

Is kisspeptin the same as gonadorelin?

No. Kisspeptin acts upstream of GnRH, while gonadorelin is synthetic GnRH itself. [10][11][1][2]

Does kisspeptin boost testosterone?

Not proven. Kisspeptin can stimulate GnRH/LH/FSH in study contexts, but broad testosterone or libido protocols are not established. [10][11][1][2]

Myths & misconceptions

Myth

Fertility-axis activity means libido enhancement.

Reality

Reproductive hormone signaling and libido are related but not interchangeable outcomes. [1][2][3][4]

Myth

Upstream stimulation is automatically safer.

Reality

Upstream reproductive-axis manipulation still needs hormone and fertility supervision. [1][2][3][4]

History & discovery

Kisspeptin was first known through KISS1 and metastasis-suppressor biology before reproductive endocrinology made it central to GnRH, puberty, fertility, and gonadotropin signaling. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]

Human reproductive-endocrine reviews established kisspeptin as an upstream regulator of GnRH neurons and LH/FSH signaling. That reframed kisspeptin from gene biology into fertility pharmacology. [1][2][3][4]

Kisspeptin-54 oocyte-maturation trials and later intranasal gonadotropin-release work tested route-specific reproductive responses. That history supports fertility research, not generic libido or testosterone claims. [1][2][3][4]

Published research 12 studies

[1]

The kisspeptin-GnRH pathway in human reproductive health and disease.

Hum Reprod Update, 2014 Jul-Aug. review.

[2]

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.

J Clin Invest, 2014 Aug. human clinical.

[3]

A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.

Hum Reprod, 2017 Sep 1. human clinical.

[4]

Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans.

EBioMedicine, 2025 May. human clinical.

[5]

Hypothalamic neurokinin signalling and its application in reproductive medicine.

Pharmacol Ther, 2022 Feb. review.

[6]

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.

Fertil Steril, 2024 Jan. human clinical.

[7]

Selective loss of kisspeptin signaling in oocytes causes progressive premature ovulatory failure.

Hum Reprod, 2022 Apr 1. animal.

[8]

Effect of post-mating TAK-683 (Kisspeptin analog) treatment on luteal morphology and function in suckling goats with lactational anestrus.

Anim Reprod Sci, 2026 Jan. animal.

[9]

Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders.

J Clin Invest, 2020 Dec 1. human clinical.

[10]

Drugs@FDA/openFDA query for Kisspeptin

U.S. Food and Drug Administration. database query.

[11]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[12]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.